For decades, Alzheimer’s disease has been framed as a one‑way path. Once memory fades and thinking slows, the prevailing view has been that the damage cannot be undone. Treatments have largely aimed to delay decline or reduce symptoms, not to restore what has been lost.

That long‑held assumption is now being questioned by a study that has captured attention across the neuroscience community.

Researchers working with advanced mouse models of Alzheimer’s disease have shown that a new experimental drug can reverse signs of brain damage and restore cognitive function, even after the disease is well established.

The findings suggest that under certain conditions, the brain may retain a capacity for repair. If confirmed in humans, the implications would be profound.

Alzheimer’s disease is the most common cause of dementia worldwide. In the United States alone, more than seven million people aged 65 and over are living with the condition, and numbers are rising as populations age. In Malaysia, Alzheimer’s prevalence is significant and rising, with studies showing about 8.5% of older adults (around 200,000-260,000 people in 2020) affected, a number projected to triple by 2050.

Alzheimer’s accounts for roughly 60 to 80 per cent of all dementia cases. Memory loss, confusion, and impaired reasoning gradually interfere with daily life, independence, and identity. Despite decades of research, effective disease‑modifying treatments remain limited.

Much of Alzheimer’s research has centred on two hallmark proteins: amyloid beta and tau. In the diseased brain, amyloid accumulates into plaques, while tau forms tangles inside neurons.

These changes disrupt communication between brain cells and trigger inflammation, oxidative stress, and cell death. Many experimental therapies have tried to clear these proteins or prevent their formation. Success has been mixed, and true reversal of cognitive decline has remained elusive.

The new study published in Cell Reports Medicine takes a different approach. Instead of targeting protein build‑up directly, scientists focused on the brain’s energy system. At the centre of this system is nicotinamide adenine dinucleotide, better known as NAD⁺. This molecule plays a critical role in cellular energy production, DNA repair, and stress resistance. Every cell depends on it, particularly neurons, which have high energy demands.

NAD⁺ levels naturally decline with age. Previous research has linked this decline to several age‑related conditions, including metabolic disorders and neurodegenerative diseases. In Alzheimer’s disease, the drop appears to be more severe. Analysis of human brain samples has revealed approximately a 30 per cent reduction in NAD⁺ compared with age‑matched controls. Such a deficit may leave brain cells vulnerable to damage and unable to recover from stress.

Scientists involved in the new research hypothesised that disrupted NAD⁺ balance might be more than a consequence of Alzheimer’s disease. It could be a driving force. If so, restoring that balance might allow brain cells to stabilise, repair themselves, and regain function.

To test this idea, researchers used two genetically engineered mouse models of Alzheimer’s disease. One model mimicked abnormal amyloid processing, while the other reflected pathological changes in the tau protein. Together, they represented distinct biological routes to the same disease. Importantly, some of the animals had already developed advanced symptoms, including memory impairment and significant brain pathology.

The team treated the mice with an experimental compound known as P7C3‑A20. This drug is not a supplement and does not add NAD⁺ directly. Instead, it protects the body’s existing supply by slowing excessive breakdown of the molecule. By supporting what is known as the NAD⁺ salvage pathway, the compound helps cells maintain normal energy balance without pushing levels beyond their natural range.

Previous studies had shown that the compound could halt neurodegeneration after traumatic brain injury in animals, even when treatment began long after the initial damage. Those earlier results raised an intriguing question. Could the same mechanism work in a chronic, progressive disease like Alzheimer’s?

The answer, at least in mice, appears to be yes. In early stages of disease, treatment prevented the development of key pathological features. More strikingly, in mice with advanced Alzheimer’s‑like changes, the drug produced a marked reversal of damage.

Treated animals showed significant improvements in learning and memory tasks. Their performance approached that of healthy control mice. Examination of brain tissue revealed multiple biological benefits. The integrity of the blood–brain barrier improved, reducing the leakage that often worsens inflammation. Levels of oxidative stress fell. DNA damage decreased. Neuroinflammation was dampened. Synaptic plasticity, the ability of neurons to strengthen and adapt their connections, was restored.

The researchers also measured blood levels of phosphorylated tau 217, a biomarker increasingly used in Alzheimer’s diagnosis and monitoring. Levels of this marker dropped significantly after treatment, suggesting a reduction in ongoing tau‑related brain injury.

Taken together, the findings challenge the idea that Alzheimer’s disease is inevitably progressive and irreversible. They suggest that, at least in some contexts, the brain retains a capacity for recovery if its fundamental energy systems are stabilised.

This approach stands apart from many existing strategies. Rather than targeting specific proteins or pathways unique to Alzheimer’s, it focuses on a core aspect of cellular health shared across many cell types.

NAD⁺ supports DNA repair, regulates inflammation, and fuels mitochondria, the energy generators of the cell. By preserving this molecule, neurons may be better equipped to survive, function, and rebuild.

The results are particularly notable because they were observed in two different models of the disease. This raises the possibility that restoring energy balance could be effective across diverse forms of Alzheimer’s, regardless of the initial trigger. That breadth has been difficult to achieve with protein‑targeting therapies.

The study also touches on an area of growing public interest: NAD⁺ supplementation. Products claiming to boost NAD⁺ levels are widely marketed as anti‑ageing aids. However, evidence for their benefits in humans is limited, and there are unresolved safety questions. Some scientists have raised concerns that artificially elevating NAD⁺ levels could, in theory, support the growth of existing cancer cells by enhancing their metabolism.

The compound used in this research avoids that risk by maintaining NAD⁺ within normal physiological limits. It does not flood the system. Instead, it preserves balance. That distinction may prove important if similar strategies move towards clinical testing.

Enhancing brain resilience and repairing damage is an appealing concept, but the work remains at a preclinical stage. Mouse models, even sophisticated ones, do not fully replicate the complexity of human Alzheimer’s disease. Many treatments that succeed in animals fail in people.

Nevertheless, the study represents an important proof of concept. It shows that targeting brain energy metabolism can influence disease progression and, under certain conditions, reverse established pathology. It also broadens the conversation about what might be possible in Alzheimer’s treatment.

The next steps are clear but challenging. Researchers need to identify which aspects of energy balance are most critical for recovery. They must determine optimal dosing, treatment timing, and long‑term safety. Carefully designed clinical trials will be essential to assess whether the approach can work in humans and, if so, in which patients.

There is also the question of combination therapy. Restoring energy balance may complement other treatments, such as those targeting amyloid or tau, lifestyle interventions, or anti‑inflammatory strategies. Alzheimer’s disease is multifactorial, and a single solution is unlikely to fit all.

For patients and families affected by Alzheimer’s, the idea of reversal has long seemed out of reach. While it would be premature to promise a cure, studies like this introduce a note of cautious optimism. They suggest that the brain is not always a passive victim of disease. Under the right conditions, it may be capable of repair.

As the global burden of dementia continues to grow, innovative approaches are urgently needed. Shifting the focus from damage control to restoration marks a conceptual change in the field. Whether this change will translate into effective treatments for people remains to be seen. What is clear is that the boundaries of what researchers consider possible are expanding.

In the meantime, the study adds momentum to a growing body of work exploring the biology of ageing and brain resilience. It underscores the importance of fundamental cellular processes, such as energy metabolism, in neurodegenerative disease. Most of all, it reminds the scientific community that long‑held assumptions deserve to be tested and new information is always updated.

If future trials confirm these findings, the narrative around Alzheimer’s disease could change. From inevitable decline to potential recovery. From managing loss to restoring function. For now, the results offer a compelling glimpse of what might lie ahead.